Skip to main content
. 2014 Oct 11;5(23):12448–12458. doi: 10.18632/oncotarget.2558

Figure 2. Early FCH-PET-CT progression on abiraterone treatment.

Figure 2

Baseline FCH-PET/CT shows multiple areas of increased radiotracer uptake indicative of extensive bone metastases. Treatment with abiraterone resulted in bone progression of FCH-PET/CT scans at week 4 confirmed at week 16.